FTC puts conditions on Sun Pharmaceutical’s proposed acquisition of Ranbaxy
MLex Summary: Pharmaceutical companies Sun Pharmaceutical Industries and Ranbaxy Laboratories have agreed to divest Ranbaxy’s interests in generic minocycline tablets in order to settle US Federal Trade Commission charges that Sun’s $4 billion buyout...To view the full article, register now.
Already a subscriber? Click here to view full article